The latest evidence revealed an unexpected augmented cytotoxic activity of CD3+CD4-CD8- double-negative T cells (DNTs) and CD8+ lymphocytes upon treatment with venetoclax and azacytidine in de novo AML [100]. Here, CD8A is linked to acute myeloid leukemia.